Compare · DXCM vs LUCD
DXCM vs LUCD
Side-by-side comparison of DexCom Inc. (DXCM) and Lucid Diagnostics Inc. (LUCD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and LUCD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 143.1x LUCD ($196.4M).
- Over the past year, DXCM is down 14.9% and LUCD is down 25.3% - DXCM leads by 10.4 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 1 for LUCD).
- DXCM has more recent analyst coverage (25 ratings vs 6 for LUCD).
- Company
- DexCom Inc.
- Lucid Diagnostics Inc.
- Price
- $72.84+0.38%
- $0.96-4.59%
- Market cap
- $28.11B
- $196.4M
- 1M return
- +20.73%
- -11.19%
- 1Y return
- -14.94%
- -25.30%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 26
- 1
- Recent ratings
- 25
- 6
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest LUCD
- Director Matheis Dennis bought $245,270 worth of shares (245,000 units at $1.00), increasing direct ownership by 31% to 1,033,443 units (SEC Form 4)
- PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
- Lucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
- SEC Form 10-Q filed by Lucid Diagnostics Inc.
- PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
- SEC Form DEFA14A filed by Lucid Diagnostics Inc.
- SEC Form DEF 14A filed by Lucid Diagnostics Inc.
- Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
- Amendment: New insider Lee Victoria Tou-Ho claimed ownership of 650,000 shares (SEC Form 3)